Abattis Bioceuticals Corp. (ATTBF)

[nilliwillis]

So I went back to try and find more information about this company.


<><><><><><><><><><>
Abattis Removed From BCSC Temporary Order
8:27 am ET January 17, 2019 (Globe Newswire) Print
<><><><><><><><><><>

Abattis Bioceuticals Corp (the "Company" or "Abattis") (CSE:ATT) (OTC:ATTBF) is pleased to announce that the temporary order from the British Columbia Securities Commission ("BCSC"), issued on November 26, 2018 (the "Order"), has not been extended against Abattis.
>>>>>>>>>>>>>>>>>>>>
Abattis is STILL not trading since the halt, but their press release say that they are OK, Hummm, smoke to raise the stock price.

<><><><><><><><><><><><>
"Update on Trading Halt
<><><><><><><><><><><><>

Further to the Company’s news release dated February 18, 2019, trading of the Company’s common shares continues to be halted on the Canadian Securities Exchange until the Company files its financial statements for the year ended September 30, 2018 (the “Financials”)."

>>>>>>>>>>>>>>>>>>>>>>>>
Well, no, not really. It's Not the year end financials they are waiting for, it's an explanation of their actions the that the financials will prove out. (SEE BELOW) So if they did break the law they can't show the books so they will stall till such time as law enforcement takes over. More Smoke to raise the stock price
<><><><><><><><>
The Actual complaint from the British Columbia Securities Commission . . ..

https://www.bcsc.bc.ca/Enforcement/Decisions/
https://www.bcsc.bc.ca/Enforcement/Decisions/PDF/2019_BCSECCOM_14/

I found Abbatis listed as:

14]
With respect to the other seven Issuers (Kootenay, Affinor
, Beleave, Liht, PreveCeutical,Speakeasy and Abattis), the executive director had obtained (in addition to publicly available information relating to private placements and news releases) trading records of
certain of the Non
-
Issuer Respondents.
[15]
That information reveals that the following occurred with respect to each of these seven Issuers:
-
each of the seven Issuers carried out private placements where certain of the Non-Issuer Respondents comprised all (or virtually all) of the subscribers;
-
these Issuers purported to use the Consultant Exemption (in all but a few instances) in connection with their distributions to the subscribers; and most of the respondent subscribers in the private placements, although not all of them, sold all of the shares they acquired from the seven Issuers soon after the closing of the private placements at an average selling price (in all but a few
instances) which was a substantial discount from the price at which those shares were acquired in the private placements.

<><><><><><><><><><><><><><><>

Which seems to reinforce my previous comment.

The ""New" company that they acquired either knows nothing about how things work being from the Netherlands, OR since they are out of the country they are a little risk from the BCSC and will just continue to bleed funds from the company.

<!><!>!<>!<>!<>!<>!<>!<>!<>
There is a hearing on 04/09/2019


Abattis Bioceuticals Corp.; 1153307 B.C. Ltd.; Executive Director
Date Opened: 2018-11-26
Hearing Type: Enforcement
Allegations: Illegal distribution
Hearing Dates: 2018-12-07; 2019-04-09;
Panel:Nigel P Cave - Chair, Judith Downes, Audrey T. Ho
Please Note:
Temporary Order issued. On January 15, 2019, the Panel extended and modified temporary orders for some of the respondents to April 10, 2019. The panel did not extend temporary orders against other respondents. On April 9, 2019, at 10:00am, the Panel will hear the Executive Director’s application to extend the temporary orders.